201 related articles for article (PubMed ID: 17488741)
21. In vitro recrudescence of Plasmodium falciparum parasites suppressed to dormant state by atovaquone alone and in combination with proguanil.
Thapar MM; Gil JP; Björkman A
Trans R Soc Trop Med Hyg; 2005 Jan; 99(1):62-70. PubMed ID: 15550263
[TBL] [Abstract][Full Text] [Related]
22. Molecular surveillance of mutations in the cytochrome b gene of Plasmodium falciparum in Gabon and Ethiopia.
Gebru T; Hailu A; Kremsner PG; Kun JF; Grobusch MP
Malar J; 2006 Nov; 5():112. PubMed ID: 17118179
[TBL] [Abstract][Full Text] [Related]
23. Atovaquone/proguanil resistance in Africa: a case report.
David KP; Alifrangis M; Salanti A; Vestergaard LS; Rønn A; Bygbjerg IB
Scand J Infect Dis; 2003; 35(11-12):897-8. PubMed ID: 14723376
[TBL] [Abstract][Full Text] [Related]
24. Malarone treatment failure not associated with previously described mutations in the cytochrome b gene.
Wichmann O; Muehlen M; Gruss H; Mockenhaupt FP; Suttorp N; Jelinek T
Malar J; 2004 Jun; 3():14. PubMed ID: 15186499
[TBL] [Abstract][Full Text] [Related]
25. Sequence analysis of Plasmodium falciparum cytochrome b in multiple geographic sites.
Ekala MT; Khim N; Legrand E; Randrianarivelojosia M; Jambou R; Fandeur T; Menard D; Assi SB; Henry MC; Rogier C; Bouchier C; Mercereau-Puijalon O
Malar J; 2007 Dec; 6():164. PubMed ID: 18086297
[TBL] [Abstract][Full Text] [Related]
26. Atovaquone/Proguanil Resistance in an Imported Malaria Case in Chile.
Chenet SM; Oyarce A; Fernandez J; Tapia-Limonchi R; Weitzel T; Tejedo JR; Udhayakumar V; Jercic MI; Lucchi NW
Am J Trop Med Hyg; 2021 Mar; 104(5):1811-1813. PubMed ID: 33782210
[TBL] [Abstract][Full Text] [Related]
27. Mutation in pfmdr1 gene in chloroquine-resistant Plasmodium falciparum isolates, Southeast Iran.
Jalousian F; Dalimi A; Samiee SM; Ghaffarifar F; Soleymanloo F; Naghizadeh R
Int J Infect Dis; 2008 Nov; 12(6):630-4. PubMed ID: 18926753
[TBL] [Abstract][Full Text] [Related]
28. Short report: no evidence of cardiotoxicity of atovaquone-proguanil alone or in combination with artesunate.
Gupta RK; Van Vugt M; Paiphun L; Slight T; Looareesuwan S; White NJ; Nosten F
Am J Trop Med Hyg; 2005 Aug; 73(2):267-8. PubMed ID: 16103586
[TBL] [Abstract][Full Text] [Related]
29. Creating and Validating Ligase Primers to Detect Single Nucleotide Polymorphisms Associated with Atovaquone Resistance in Plasmodium falciparum.
Alruwaili M; Elahi R; van Schalkwyk D; Sutherland C; Shapiro T; Prigge S; Sullivan D
Am J Trop Med Hyg; 2023 Apr; 108(4):777-782. PubMed ID: 36878214
[TBL] [Abstract][Full Text] [Related]
30. [What is the value of the combination atovaquone-proguanil for the clinician?].
Delmont J
Med Trop (Mars); 2002; 62(3):232-6. PubMed ID: 12244917
[TBL] [Abstract][Full Text] [Related]
31. Advanced Molecular Detection of Malarone Resistance.
Talundzic E; Plucinski MM; Biliya S; Silva-Flannery LM; Arguin PM; Halsey ES; Barnwell JW; Vannberg F; Udhayakumar V
Antimicrob Agents Chemother; 2016 Jun; 60(6):3821-3. PubMed ID: 27001821
[TBL] [Abstract][Full Text] [Related]
32. Multiple cytochrome B mutations may cause atovaquone resistance.
Meshnick SR; Trumpower B
J Infect Dis; 2005 Mar; 191(5):822; author reply 822-3. PubMed ID: 15688308
[No Abstract] [Full Text] [Related]
33. First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.
Savini H; Bogreau H; Bertaux L; Bouchiba H; Kraemer P; Parzy D; Garnotel E; Rogier C; Simon F; Pradines B
Antimicrob Agents Chemother; 2008 Jun; 52(6):2283-4. PubMed ID: 18411319
[No Abstract] [Full Text] [Related]
34. Atovaquone-proguanil for prophylaxis and treatment of malaria.
Marra F; Salzman JR; Ensom MH
Ann Pharmacother; 2003 Sep; 37(9):1266-75. PubMed ID: 12921511
[TBL] [Abstract][Full Text] [Related]
35. Atovaquone-Proguanil Remains a Potential Stopgap Therapy for Multidrug-Resistant Plasmodium falciparum in Areas along the Thai-Cambodian Border.
Saunders DL; Chaorattanakawee S; Gosi P; Lanteri C; Somethy S; Kuntawunginn W; Ittiverakul M; Chann S; Gregory C; Chuor CM; Prom S; Spring MD; Lon C
Antimicrob Agents Chemother; 2015 Dec; 60(3):1896-8. PubMed ID: 26711753
[TBL] [Abstract][Full Text] [Related]
36. Molecular characterization of the cytochrome b gene and in vitro atovaquone susceptibility of Plasmodium falciparum isolates from Kenya.
Ingasia LA; Akala HM; Imbuga MO; Opot BH; Eyase FL; Johnson JD; Bulimo WD; Kamau E
Antimicrob Agents Chemother; 2015 Mar; 59(3):1818-21. PubMed ID: 25583715
[TBL] [Abstract][Full Text] [Related]
37. Plasmodium falciparum outwits Malarone, protector of travellers.
Crabb C
Bull World Health Organ; 2003; 81(5):382-3. PubMed ID: 12856058
[No Abstract] [Full Text] [Related]
38. Atovaquone/proguanil for the prophylaxis and treatment of malaria.
Patel SN; Kain KC
Expert Rev Anti Infect Ther; 2005 Dec; 3(6):849-61. PubMed ID: 16307498
[TBL] [Abstract][Full Text] [Related]
39. Emergence of resistance to atovaquone-proguanil in malaria parasites: insights from computational modeling and clinical case reports.
Cottrell G; Musset L; Hubert V; Le Bras J; Clain J;
Antimicrob Agents Chemother; 2014 Aug; 58(8):4504-14. PubMed ID: 24867967
[TBL] [Abstract][Full Text] [Related]
40. Spread and evolution of Plasmodium falciparum drug resistance.
Mita T; Tanabe K; Kita K
Parasitol Int; 2009 Sep; 58(3):201-9. PubMed ID: 19393762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
